Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease
Yonsei Medical Journal
; : 113-118, 2018.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-742496
Biblioteca responsável:
WPRO
ABSTRACT
PURPOSE:
Intravenous immunoglobulin (IVIG) is the standard treatment for Kawasaki disease (KD). However, there is still no standard treatment for IVIG-resistant KD. This study aimed to evaluate the efficacy of low-dose methotrexate (MTX) as a treatment for IVIG-resistant KD. MATERIALS ANDMETHODS:
We retrospectively analyzed 10-year data for patients with IVIG-resistant KD who were administered MTX at Severance Children's Hospital.RESULTS:
The subjects included 75 patients with KD aged 5 months to 9.2 years who had been administered MTX. Their maximum body temperatures decreased significantly within 24 h of therapy. The patients' C-reactive protein levels were significantly lower 1 week after administering the first dose of MTX than those before treatment. No adverse effect for MTX was observed.CONCLUSION:
MTX treatment of IVIG-resistant KD resulted in rapid defervescence, improvement of clinical symptoms, and normalization of acute-phase reactants in all patients. Thus, MTX could be a candidate treatment for IVIG-resistant KD.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Esteroides
/
Proteína C-Reativa
/
Demografia
/
Metotrexato
/
Estudos Retrospectivos
/
Resultado do Tratamento
/
Imunoglobulinas Intravenosas
/
Vasos Coronários
/
Relação Dose-Resposta a Droga
/
Quimioterapia Combinada
Tipo de estudo:
Estudo observacional
/
Fatores de risco
Aspecto:
Determinantes sociais da saúde
Limite:
Criança
/
Criança, pré-escolar
/
Feminino
/
Humanos
/
Lactente
/
Masculino
Idioma:
Inglês
Revista:
Yonsei Medical Journal
Ano de publicação:
2018
Tipo de documento:
Artigo